Parkinson's disease: From bench to bedside

A Draoui; O El Hiba; A Aimrane; A El Khiat; H Gamrani

doi:10.1016/j.neurol.2019.11.002

Parkinson's disease: From bench to bedside

Rev Neurol (Paris). 2020 Sep;176(7-8):543-559. doi: 10.1016/j.neurol.2019.11.002. Epub 2020 Jan 9.

Authors

A Draoui¹, O El Hiba², A Aimrane¹, A El Khiat¹, H Gamrani³

Affiliations

¹ Neuroscience, Pharmacology and Environment Unit, Faculty of Sciences Semlalia, Cadi Ayyad University, Avenue My Abdellah, B.P. 2390, Marrakesh, Morocco.
² Neuroscience, Pharmacology and Environment Unit, Faculty of Sciences Semlalia, Cadi Ayyad University, Avenue My Abdellah, B.P. 2390, Marrakesh, Morocco; Laboratory of Biotechnologies, Biochemistry and Nutrition, Faculty of Sciences, Chouaib Doukkali University El Jadida, Route Ben Maachou, B.P. 20, Avenue des Facultés, El Jadida, Morocco. Electronic address: omar.elhiba@edu.uca.ac.ma.
³ Neuroscience, Pharmacology and Environment Unit, Faculty of Sciences Semlalia, Cadi Ayyad University, Avenue My Abdellah, B.P. 2390, Marrakesh, Morocco. Electronic address: gamrani54@gmail.com.

PMID: 31928746
DOI: 10.1016/j.neurol.2019.11.002

Abstract

Parkinson's disease is a very complex public health problem with different etiologies and a wide range of clinical features including motor and non-motor symptoms. The aim of the current report is to review the latest advances in the understanding of PD etiologies, diagnosis, epidemiology and an overview of the earlier and latest advances in the management of PD, from L-DOPA to adult astroglia reprogramming into dopaminergic neurons in vivo.

Keywords: Epidemiology; Etiology; Neuroinflammation; Parkinson's disease; Pathophysiology; Risk factors; Symptomatology; Treatments.

Publication types

Review

MeSH terms

Dopaminergic Neurons
Humans
Levodopa
Parkinson Disease*

Substances

Levodopa